Filing Flows

Filing Flows › 8-K events › Precision Biosciences

Precision Biosciences: regulation fd disclosure

Form 8-K filed Nov 5, 2026 · items 7.01, 8.01

FDA decisionsPrecision BioSciences Announces Late-Breaking PBGENE-HBV Data at AASLD The Liver Meeting® 2026 Further Demonstrating cccDNA Elimination and Potential to Drive Viral Cure

What the filing says

HBV Data at AASLD The Liver Meeting® 2026 Further Demonstrating cccDNA Elimination and Potential to Drive Viral Cure - Phase 1 ELIMINATE-B study successful, PBGENE-HBV Program Advancing to Phase 2-

Read the filing on SEC EDGAR →

What usually followsAcross 44,881 8-Ks reporting Item 8.01 (other events) in our universe, the stock's median move the next session was +0.1% (typical size ±1.5%, up 52% of the time); over the following 21 sessions, +1.1%. Every item ranked →

Precision Biosciences at a glance

Latest quarterQ3 FY26
Revenue$10.8M
Revenue Y/Y374×
Operating margin-83.7%
IndustryBiological Products, (No Diagnostic Substances)

Precision Biosciences, Q3 FY26: revenue $10.8M (374× year over year), operating margin -83.7%. The chart follows the revenue to costs, profit and cash.

Precision Biosciences: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent fda decisions

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.